Ramb - Janeiro

rancisqueti

ssoc

ras

2017; 63(1):85-91

esumo

O papel do estresse oxidativo na fisiopatologia da sín-

drome metabólica

A síndrome metabólica apresenta elevada prevalência na

população mundial. De acordo com os componentes que

a classificam, nota-se que está intimamente relacionada

com a obesidade. Essas duas condições se iniciam com o

aumento do tecido adiposo abdominal, o qual é metabo-

licamente mais ativo, contendo uma quantidade maior

de macrófagos residentes em comparação com outros

depósitos de gordura. Essa situação favorece a inflamação

e o estresse oxidativo, ambos precursores de diversas com-

plicações, mas principalmente as envolvidas na síndrome

metabólica, como resistência à insulina, hipertensão ar-

terial e hiperlipidemia. Uma maneira de bloquear os efei-

tos do estresse oxidativo seria pelo sistema de defesa an-

tioxidante, o qual anula os radicais livres em excesso. É

sabido que indivíduos portadores de síndrome metabó-

lica e obesos apresentam um alto consumo de gorduras,

açúcares oriundos de alimentos industrializados com alto

teor de sódio e uma baixa ingestão de frutas e verduras,

apresentando uma condição de estresse oxidativo contí-

nuo. A manutenção de hábitos alimentares saudáveis,

com a inclusão de alimentos ricos em antioxidantes, po-

deria prevenir ou retardar o surgimento da SM.

Palavras-chave

: estresse oxidativo, síndrome metabóli-

ca, obesidade.

eferences

Steckhan N, Hohmann CD, Kessler C, Dobos G, Michalsen A, Cramer H.

Effects of different dietary approaches on inflammatory markers in patientes

with metabolic syndrome: a systematic review and meta-analysis. Nutrition.

2016; 32(3):338-48.

Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract.

2014; 2014:943162.

Expert Panel on Detection, Evaluation, and Treatment of High Blood

Cholesterol in Adults. Executive Summary of The Third Report of The

National Cholesterol Education Program (NCEP) Expert Panel on Detection,

Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult

Treatment Panel III). JAMA. 2001; 285(19):2486-97.

4. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus

Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005;

366(9491):1059-62.

5. World Health Organization (WHO). Diet, nutrition and the prevention of

chronic diseases. Geneva: WHO/FAO Expert consultation on diet, nutrition

and the prevention of chronic diseases; 2002.

6. Dupuy AM, Jaussent I, Lacroux A, Durant R, Cristol JP, Delcourt C. Waist

circumference adds to the variance in plasma C-reactive protein levels in elderly

patients with metabolic syndrome. Gerontology. 2007; 53(6):329-39.

Luna-Luna M, Medina-Urrutia A, Vargas-Alarcón G, Coss-Rovirosa F, Vargas-

Barrón J, Pérez-Méndez O. Adipose tissue in metabolic syndrome: onset and

progression of atherosclerosis. Arch Med Res. 2015; 46(5):392-407.

8. Yao L, Herlea-Pana O, Heuser-Baker J, Chen Y, Barlic-Dicen J. Roles of the

chemokine system in development of obesity, insulin resistance, and

cardiovascular disease. J Immunol Res. 2014; 2014:181450.

Francisqueti FV, Nascimento AF, Corrêa CR. Obesidade, inflamação e

complicações metabólicas. Nutrire. 2015; 40(1):81-9.

10.

Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic

syndrome. Rev Endocr Metab Disord. 2014; 15(4):277-87.

11. Cotillard A, Poitou C, Torcivia A, Bouillot JL, Dietrich A, Klöting N, et al.

Adipocyte size threshold matters: link with risk of type 2 diabetes and

improved insulin resistance after gastric bypass. J Clin Endocrinol Metab.

2014; 99(8):E1466-70.

12.

Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between

adipocyte size and adipokine expression and secretion. J Clin Endocrinol

Metab. 2007; 92(3):1023-33.

13. Andrade-Oliveira V, Câmara NOS, Moraes-Vieira PM. Adipokines as drug

targets in diabetes and underlying disturbances. J Diabetes Res. 2015;

2015:681612.

14. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the

metabolic syndrome. Am J Cardiol. 1998; 81(4A):18B-25B.

15.

Borer KT. Counterregulation of insulin by leptin as key component of

autonomic regulation of body weight. World J Diabetes. 2014; 5(5):606-29.

16.

Bhattacharya I, Domínguez AP, Drägert K, Humar R, Haas E, Battegay EJ.

Hypoxia potentiates tumor necrosis factor-alpha induced expression of

inducible nitric oxide synthase and cyclooxygenase-2 in white and brown

adipocytes. Biochem Biophys Res Commun. 2015; 461(2):287-92.

17.

Kosacka J, Kern M, Klöting N, Paeschke S, Rudich A, Haim Y, et al. Autophagy

in adipose tissue of patients with obesity and type 2 diabetes. Mol Cell

Endocrinol. 2015; 409:21-32.

18.

Netzer N, Gatterer H, Faulhaber M, Burtscher M, Pramsohler S, Pesta D.

Hypoxia, oxidative stress and fat. Biomolecules. 2015; 5(2):1143-50.

19. Ferreira AL, Yeum KJ, Matsubara LS, Matsubara BB, Correa CR, Pereira EJ, et

al. Doxorubicin as an antioxidant: maintenance of myocardial levels of lycopene

under doxorubicin treatment. Free Radic Biol Med. 2007; 43(5):740-51.

20. Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant

capacity in the hydrophilic and lipophilic compartments of human plasma.

Arch Biochem Biophys. 2004; 430(1):97-103.

21. Grant CM. Metabolic reconfiguration is a regulated response to oxidative

stress. J Biol. 2008;7(1):1.

22.

Poli G, Schaur RJ, Siems WG, Leonarduzzi G. 4-hydroxynonenal: a mem-

brane lipid oxidation product of medicinal interest. Med Res Rev. 2008;

28(4):569-631.

23.

Dandona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS. Macronutrient

intake induces oxidative and inflammatory stress: potential relevance to

atherosclerosis and insulin resistance. Exp Mol Med. 2010; 42(4):245-53.

24. Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M. Intervention

strategies to inhibit protein carbonylation by lipoxidation-derived reactive

carbonyls. Med Res Rev. 2007; 27(6):817-68.

25.

Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz

RM. Oxidative stress and human hypertension: vascular mechanisms,

biomarkers, and novel therapies. Can J Cardiol. 2015; 31(5):631-41.

26. Wong WT, Tian XY, Huang Y. Endothelial dysfunction in diabetes and

hypertension: cross talk in RAS, BMP4, and ROS-dependent COX-2-derived

prostanoids. J Cardiovasc Pharmacol. 2013; 61(3):204-14.

27.

Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways?

A circuitous relationship between reactive oxygen species and cyclo-oxygenase

in hypertension. Clin Sci (Lond). 2014; 126(2):111-21.

28. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative

stress in human hypertension: association with antihypertensive treatment,

gender, nutrition, and lifestyle. Free Radic Biol Med. 2004; 36(2):226-32.

29. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and

type 2 diabetes mellitus. World J Diabetes. 2015; 6(3):456-80.

30.

Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role

in multiple forms of insulin resistance. Nature. 2006; 440:944-8.

31.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;

444(7121):860-7.

32.

Poljsak B, Šuput D, Milisav I. Achieving the balance between ROS and

antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev.

2013; 2013:956792.

33.

Maiani G, Castón MJ, Catasta G, Toti E, Cambrodón IG, Bysted A, et al.

Carotenoids: actual knowledge on food sources, intakes, stability and